Literature DB >> 10643153

Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.

T Hongo1, S Yamada, S Yajima, C Watanabe, Y Fujii, H Kawasaki, M Yazaki, R Hanada, Y Horikoshi.   

Abstract

The purpose of this study was to investigate the biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia (ALL). We carried out in vitro tests with a 4-day culture and a methyl-thiazol-tetrazolium assay on bone marrow samples from 209 children newly diagnosed with ALL. After testing the resistance of leukemic cells to 14 drugs, we classified the patients into two groups according to their sensitivity to three drugs (prednisolone, L-asparaginase, and vincristine) used in remission induction therapy. The three-drug resistant group (RR: sensitive to no drugs or to one drug) correlated with both short-term and long-term treatment failure. Three-year event-free survival (95% confidence interval) for the sensitive group (SS: sensitive to two or three drugs) was 0.813 (0.773-0.853) and that of the RR group was 0.616 (0.569-0.669) (P = 0.0001). Univariate analysis showed that Philadelphia-chromosome (Ph1) positivity and immunophenotype of mixed lineage were also prognostic factors in the 209 patients. The prognosis of the SS/RR drug resistance profile within 14 Ph1 patients was marginally significant (P = 0.062). Multivariate Cox regression analysis showed that Ph1 was an overwhelmingly adverse factor in event-free survival, with a relative hazard of 5.37 (2.57-11.21, P < 0.0001), followed by RR, with a relative hazard of 2.98 (1.69-5.25, P = 0.0001). Furthermore, we clarified the characteristics of the RR group by examination of the pattern of drug resistance to other drugs in comparison with the SS group. The leukemic cells of RR patients were more resistant than those of SS patients (P < 0.0001) to all the drugs tested, with resistance ratios of 1.6 to 13.1 (mean 3.4). In conclusion, in vitro three-drug resistance at the initial stage is an important independent predictor of treatment failure for both induction response and long-term outcome in childhood ALL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10643153

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  6 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.

Authors:  Teruaki Hongo; Shuichi Okada; Noriko Inoue; Sayuri Yamada; Shuhei Yajima; Chieko Watanabe; Yuji Fujii; Yasuo Horikoshi
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

3.  The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.

Authors:  Amy Holleman; Monique L den Boer; Renée X de Menezes; Meyling H Cheok; Cheng Cheng; Karin M Kazemier; Gritta E Janka-Schaub; Ulrich Göbel; Ulrike B Graubner; William E Evans; Rob Pieters
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

4.  Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.

Authors:  S Yamada; T Hongo; S Okada; C Watanabe; Y Fujii; H Hori; M Yazaki; R Hanada; Y Horikoshi
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

5.  Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols.

Authors:  Amy Holleman; Monique L den Boer; Meyling H Cheok; Karin M Kazemier; Deqing Pei; James R Downing; Gritta E Janka-Schaub; Ulrich Göbel; Ulrike B Graubner; Ching-Hon Pui; William E Evans; Rob Pieters
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

Review 6.  Pharmacogenetics in acute lymphoblastic leukemia.

Authors:  Meyling H Cheok; Nicolas Pottier; Leo Kager; William E Evans
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.